Gerresheimer swings to €318.7m loss in 2025

Gerresheimer has recorded a consolidated net loss of €318.7m in financial year 2025, versus adjusted net income of €84.3m a year earlier.

The medical and cosmetic packaging maker's result was affected by non-cash depreciation, amortisation and impairments of around €521.5m, along with exceptional charges including restructuring costs of approximately €71.8m.

The impairments were mainly linked to technology and development projects at Sensile Medical, goodwill, and the assets of Gerresheimer Moulded Glass Chicago in the US.

Group revenue increased by 16.6% to €2.3bn from €1.9bn in 2024 on an adjusted basis, reflecting the first-time consolidation of Bormioli Pharma.

Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) came to €384m, against an adjusted figure of €388m in the previous year.

As a result of the negative consolidated net income, which is partly reflected in the separate financial statements of Gerresheimer, no dividend will be paid for 2025.

Underlying growth was led mainly by the Plastics & Devices unit, especially through demand for drug delivery devices.

In contrast, the Primary Packaging Glass unit faced weaker demand for packaging

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/gerresheimer-swings-318-7m-loss-110057123.html)